Canada: The Cannabis Frenzy

While the Canadian capital markets were volatile in 2017, market activity in the Canadian cannabis sector has achieved unprecedented highs. The $245-million investment by Constellation Brands, a NYSE-listed producer of beer, wine and spirits, in TSX-listed Canopy Growth in the fall of 2017 sparked interest across North America in the Canadian cannabis industry.

Since the Constellation Brands investment, capital markets activity in the cannabis space has soared. In the first quarter of 2018 alone, over $1.4 billion of equity was raised by cannabis companies listed on Canadian stock exchanges.

Against this backdrop, we have summarized below some of the significant developments in the cannabis sector and expected trends for 2018.

Second Reading Passes

After much speculation and debate, the federal Cannabis Act, which will legalize access to recreational cannabis and regulate the growing, production and distribution of recreational cannabis in Canada, was passed by a 44-to-29 vote on March 22, 2018, at second reading in the Senate of Canada. This marks an important milestone for the Canadian cannabis industry, as many feared that the Act would get bogged down in the Senate.

Currently, the Cannabis Act is being reviewed by five Senate committees (Aboriginal Peoples; Legal and Constitutional Affairs; National Security and Defence; Foreign Affairs and International Trade; and Social Affairs, Science and Technology), with the aim of having it receive Royal Assent by July 2018.

The Cannabis Act assigns significant responsibility for the legal framework of recreational cannabis to the provinces and territories. As a result, the provinces and territories have requested a sufficient period of time between Royal Assent and enactment of the new law in order to allow for the orderly transfer of cannabis products from federally licensed producers to provincially or territorially authorized distributors and retailers. The Government of Canada has indicated that it will accommodate this request by providing for an 8-to-12-week transition period.

Health Canada Proposes Cannabis Act Regulations

To support the implementation of the Cannabis Act, regulations will need to be enacted. On November 21, 2017, Health Canada published a consultation paper and launched a 60-day public consultation to solicit input on the regulatory approach. Health Canada received 3,218 online and 450 written submissions on the consultation paper. Most of the comments centred on packaging and labelling, security and facilitating access to the industry by "micro-cultivators."

Health Canada does not intend to pre-publish draft regulations for public comment. The final regulations will be published as soon as possible following Royal Assent to the Act.

The "Sessions Effect"

In January 2018, U.S. Attorney General Jeff Sessions rescinded three memos, collectively referred to as the Cole Memorandum, that were adopted in August 2013 under the Obama administration. The Cole Memorandum signalled a shift of government priorities away from strict enforcement of federal laws regulating cannabis and toward a more lenient approach in states that had enacted laws legalizing cannabis and implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession thereof.

Within days of Sessions rescinding the Cole Memorandum, the Canadian Securities Administrators (CSA) issued a notice advising market participants that it was considering whether the existing disclosure-based approach for issuers with U.S. cannabis-related activities, set out in an October 2017 CSA notice, remained appropriate. In February 2018, the CSA provided further guidance on staff's disclosure expectations for issuers with U.S. cannabis-related activities. The February notice reiterated the original guidance provided in October 2017 but included additional disclosure requirements, including the requirement to quantify an issuer's balance sheet and operating statement exposure to U.S. marijuana-related activities and disclosure regarding whether an issuer has obtained legal advice regarding compliance with applicable U.S. state regulatory frameworks.

Opening of the U.S. Equity Markets

The Sessions Effect did not cool U.S. investors' appetites for cannabis stocks. On February 27, 2018, shares of Cronos Group began trading on Nasdaq, becoming the first Canadian cannabis company to be listed on a U.S. stock exchange. Shortly after listing on Nasdaq, Cronos announced a $100-million cross-border bought deal offering, co-led by GMP Securities and BMO Capital Markets. This was the first cross-border offering by a cannabis company conducted pursuant to the multijurisdictional disclosure System adopted by the United States and Canada and only the second public offering led by a Canadian-bank-owned dealer.

Given the uncertain regulatory environment in the United States and the legal impediments facing U.S. cannabis companies, we expect many U.S. investors to continue to look to Canadian cannabis companies as advantageous investment opportunities. As a result, we anticipate more Canadian cannabis companies listing on U.S. stock exchanges in order to facilitate capital raising efforts in the United States.

BMO Enters the Fray

Financing of the Canadian cannabis industry has generally been dominated by the independently owned investment banks. This changed in 2018 when BMO Capital Markets co-led bought deal offerings for each of Canopy Growth and Cronos Group. The other Canadian, U.S. and global bank-owned dealers appear to be sitting on the sidelines - for now. We expect to see other Canadian-bank-owned dealers, even those with U.S. operations, jumping into the fray once recreational cannabis is legal.

Migration North?

Given the legal uncertainty in the United States, several cannabis companies with U.S. operations have listed on the Canadian Securities Exchange (CSE). Unlike the TSX or the TSX Venture Exchange, the CSE does not restrict issuers with U.S. cannabis-related activities from trading on the exchange. In March 2018, the shares of Cannex Capital Holdings Inc., a cannabis company based in Washington State that claims to be the biggest in that state, began trading on the CSE. Cannex is one of 63 CSE-listed cannabis companies, including over 14 companies with US. operations.

Big Pharma Wants In

The race is on to secure supply of cannabis products in advance of the enactment of the Cannabis Act. Many pharmacies, including Shoppers Drug Mart and Pharmasave, have applied to become licensed sellers of cannabis products and have entered into supply agreements in anticipation of the opening up of the recreational market. Even though most provincial distribution frameworks will be controlled by government-owned subsidiaries, provinces like Alberta and British Columbia have proposed a private retail framework, which could prove to be lucrative to pharmacies with operations in those provinces.

Another growing industry trend is the entry of Big Pharma. Since 2016, CannTrust Holdings Inc. has been partnering with Apotex Inc. to develop new products that will make it easier for patients to use medical cannabis. In March 2018, privately owned Tilray Inc. announced a strategic alliance with Sandoz Canada Inc., a generic drug maker, to develop and sell medical cannabis products carrying both logos.

We expect to see more partnering between national and international Big Pharma and the cannabis industry in 2018, as growing Canadian cannabis companies aim to gain access to the scale, credibility and experience that the pharmaceutical companies have to offer.

Not Out of the Woods Yet

There remains much skepticism regarding the cannabis sector. In an unhelpful turn of events, three Canadian cannabis companies recently came under attack for questionable conduct by insiders.

In February 2018, Maricann Group Inc., a CSE-listed company, announced in the middle of a public offering that the Ontario Securities Commission was conducting a review of the timing and reporting of trades in securities of the company by certain insiders and that a special committee had been appointed to review the matter. The underwriters backed out of the public offering.

In March 2018, the Ontario and Saskatchewan securities commissions, in reasons released in connection with the hostile takeover bid made by Aurora Cannabis Inc. for CanniMed Therapeutics Inc., criticized certain directors of CanniMed for sharing material non-public information with the hostile bidder. The behaviour did result in private litigation, although this was dropped when Aurora and CanniMed came to terms on a friendly deal.

Also in March 2018, a U.S.-based hedge fund raised concerns about Aphria Inc.'s proposed purchase of Nuuvera Inc. at that time. It was subsequently reported in the media that neither company had disclosed to shareholders voting on the proposed transaction that certain insiders of Aphria held shares in the target company. The disclosure would have been required if the transaction had proceeded by way of a takeover bid, but it was not a mandatory line item in the proxy circular form used for the acquisition. The omission left many questioning whether the disclosure should have been made nonetheless.


In March 2018, a German court stopped the government's tender process for 10 cultivation licences tied to long-term contracts for the supply of 6,600 kilograms of medical marijuana, on the basis that the timeline to respond was too short. A number of Canadian companies were shortlisted for the licences, including Aphria, MedReleaf Corp. and Canopy Growth. Although producers can continue to export medical cannabis to the German market in the meantime, the expected impact of the delay on the selection of the successful bidders resulted in reduced price targets for a number of Canadian cannabis companies.

The Canadian cannabis market was dealt another blow by the Barron's cover story on March 30, 2018. Barron's issued a strong warning that Canadian pot stocks were overpriced, noting that "today's investors are effectively paying 15 times the industry's cash flow five years from now." The article also raised price-forecast concerns, speculating that the rapid build-out of capacity by the 94 licensed producers in Canada created the potential for a supply glut that will drive down prices and, moreover, that recreational users will not be prepared to pay higher prices for premium brands. This news, coupled with the recent German court decision, leaves us to wonder if the cannabis frenzy will subside in 2018, to be replaced with more measured expectations.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions